SURVYR

HROW

Harrow, Inc.
$28.44
+$0.29 (1.03%)Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-31%-13%+5%+23%+41%Oct 2025Oct 2026Apr 202652w high $54.8552w low $26.96
HROWSPY
Wall St. Highest PT $88.00 (+209.4%) Wall St. Avg PT $63.00 (+121.5%)
$27$50$73$96$119POC $38Hi $88Avg $63
Underwater Drawdown %Max DD -50.3%Current -48.1%
0.0%-50.3%
Relative Strength vs SPY-41.9% vs SPYUnderperforming
+53%0%-53%
1W
+$1.16 (4.25%)
1M
−$5.16 (15.36%)
3M
−$10.01 (26.03%)
6M
−$11.26 (28.36%)
YTD
−$20.56 (41.96%)
1Y
−$10.60 (27.15%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
8 analysts · mean score 1.00
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$28.44
Average target$63.00
+$34.56 (+121.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$45.00
Median$63.00
High$88.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-07 · BTIG reiterated Buy on HROW
Initiated
2026-09-09 · Leerink Partners started covering HROW at Outperform
Reiterated
2026-08-11 · BTIG reiterated Buy on HROW
Reiterated
2026-07-21 · BTIG reiterated Buy on HROW
Reiterated
2026-05-13 · Cantor Fitzgerald reiterated Overweight on HROW
Reiterated
2026-05-12 · BTIG reiterated Buy on HROW
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.1B
P/E (next 12 months, estimated)10.3
52-week range$26.96 – $54.85
Revenue growth (latest quarter vs a year ago)+10.9%
Dividend yieldNo dividend
Analyst consensusStrong Buy (8)
Average analyst price target$63.00 (+122%)

What they do

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications.

Healthcare · Drug Manufacturers - Specialty & Generic
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for HROW yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

HROW earningsNext report in 13 days
Next report
Mon Nov 9, 2026Time not confirmed
EPS consensus$0.32 range $0.21–$0.48
Revenue consensus$99.1M 9 analysts
Last 4 quarters · EPS vs estimate
Aug 10, 2026-$0.46est -$0.24−91.7%Below estimates
May 11, 2026-$0.74est -$0.33−124.2%Below estimates
Mar 2, 2026$0.27est $0.48−43.7%Below estimates
Nov 10, 2025$0.33est $0.29+13.8%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 08:00:47 ET
24-1125-0325-0525-0825-1126-0326-0526-08-0.740.48
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$70.7M+10.9%
2026-03-31$44.2M–
2025-12-31$89.1M–
2025-09-30$71.6M–
2025-06-30$63.7M–

News & catalysts

More news
Is Harrow (HROW) Below Fair Value Based On Its Sales?
Simply Wall St. · Oct 18
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
MT Newswires · Oct 09
Do Options Traders Know Something About Harrow Stock We Don't?
Zacks · Oct 09
Is Harrow (HROW) Undervalued On Growing Conference Buzz Around Its Ophthalmic Pipeline?
Simply Wall St. · Oct 07
Harrow Completes Acquisition of Tyrvaya Nasal Spray From Viatris
MT Newswires · Oct 05
Rating changes
Reiterated
2026-10-07 · BTIG reiterated Buy on HROW
Initiated
2026-09-09 · Leerink Partners started covering HROW at Outperform
Reiterated
2026-08-11 · BTIG reiterated Buy on HROW
Reiterated
2026-07-21 · BTIG reiterated Buy on HROW
Reiterated
2026-05-13 · Cantor Fitzgerald reiterated Overweight on HROW
Reiterated
2026-05-12 · BTIG reiterated Buy on HROW

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-24 08:00:47 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026